ovarian disease: A disease involving the ovary.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleonly females |
293218 |
2. Check conditionsNone |
293218 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
220 |
4. Check minimum number of eventsNone |
220 |
5. Include endpointsNone |
220 |
6. Filter based on genotype QC (FinnGen only) |
212 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Ovarian dysfunction, other/unspecified
based on the number of shared cases.
Similar with more cases:
- Ovarian dysfunction
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1225 | 1225 | - |
| Only index persons | 1157 | 1157 | - |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | - |
| Only index persons | 0.04 | 0.04 | - |
| Median age at first event (years) | |||
| Whole population | - | 32.36 | - |
| Only index persons | - | 31.95 | - |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 212 | 212 | - |
| Unadjusted period prevalence (%) | 0.08 | 0.08 | - |
| Median age at first event (years) | 33.86 | 33.86 | - |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 220
- Matched controls
- 2200
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E28.8
ICD-10 Finland
Other ovarian dysfunction
+∞
120.1
104
*
121
Kela drug reimbursment
Severe hypofunction of sexual glands
57.2
111.0
65
16
E28.9
ICD-10 Finland
Ovarian dysfunction, unspecified
+∞
60.2
55
*
E28.3
ICD-10 Finland
Primary ovarian failure
466.4
40.5
39
*
G03FB08
ATC
dydrogesterone and estrogen; systemic
9.1
37.8
53
74
25691, ,
ICD-8 Finland
+∞
23.3
22
*
25699
ICD-8 Finland
Ovarian dysfunction, Other and unspecified
+∞
20.1
19
*
25698
ICD-8 Finland
Ovarian dysfunction, Alia definita
+∞
19.0
18
*
G03CA03
ATC
estradiol; nasal, systemic, rectal, transdermal, vaginal
3.4
16.8
147
815
N91.1
ICD-10 Finland
Secondary amenorrhoea
13.2
15.6
27
23
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
3.1
14.8
131
713
E28.2
ICD-10 Finland
Polycystic ovarian syndrome
28.6
12.2
16
6
H02AB09
ATC
hydrocortisone; systemic
15.2
10.7
17
12
62800
ICD-8 Finland
Sterility, female, Sterilitas primaria
20.0
10.4
15
8
N97.8
ICD-10 Finland
Female infertility of other origin
8.2
9.7
21
28
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.5
9.2
84
439
G03DB01
ATC
dydrogesterone; oral
2.7
8.5
56
249
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.5
8.4
21
50
C81.1
ICD-10 Finland
Nodular sclerosis classical Hodgkin lymphoma
+∞
8.4
8
*
N91.4
ICD-10 Finland
Secondary oligomenorrhoea
18.0
8.2
12
7
N97.9
ICD-10 Finland
Female infertility, unspecified
3.4
7.7
30
99
H01CA02
ATC
nafarelin; nasal
4.5
7.6
19
45
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.0
7.5
36
134
E89.4
ICD-10 Finland
Postprocedural ovarian failure
82.8
7.5
8
*
N97.0
ICD-10 Finland
Female infertility associated with anovulation
7.8
7.3
16
22
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
7.3
7
*
G03GA02
ATC
human menopausal gonadotrophin; parenteral
4.5
7.2
18
43
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
6.8
50
232
61610
ICD-8 Finland
Diseases of parametrium and pelvic peritoneum (female), Pelvic peritoneal adhesions, female
41.4
6.8
8
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.2
6.6
28
97
H02AA02
ATC
fludrocortisone; oral
71.8
6.5
7
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
6.9
6.5
15
23
A02BC05
ATC
esomeprazole; systemic
2.1
6.4
96
597
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
3.5
6.3
22
67
G03DA02
ATC
medroxyprogesterone; systemic
2.9
6.3
32
123
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
6.3
6
*
H01AC01
ATC
somatropin; parenteral
+∞
6.3
6
*
2568X
ICD-9 Finland
Ovarian dysfunction, Other ovarian dysfunction
+∞
6.3
6
*
G03FA14
ATC
dydrogesterone and estrogen; systemic
3.2
6.2
25
84
N92.6
ICD-10 Finland
Irregular menstruation, unspecified
2.8
6.1
32
125
SPAT1255
SPAT
Intravenous administration of medicine
3.9
6.1
18
49
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
51
57
11.35
43.39
1.4
1.1
21.39
9.28
u/l
4.10
40
47
39
48
9.66
30.48
1.5
1.4
0.26
0.52
nmol/l
1.27
27
40
43
60
8.66
30.42
1.6
1.1
2.07
2.65
ug/l
0.39
26
53
55
152
4.49
18.73
2.0
1.2
35.51
23.34
iu/l
1.41
48
130
20
50
4.30
7.53
1.9
1.4
30.12
21.93
u/l
0.54
20
39
77
433
2.20
6.76
3.6
2.9
0.25
0.40
e6/l
0.61
58
317
90
550
2.08
6.29
3.5
2.9
—
—
—
0
0
94
603
1.98
5.60
6.9
7.6
1.01
1.10
inr
2.45
25
198
21
69
3.26
5.38
4.0
5.0
24.49
25.10
mmol/l
0.24
21
69
97
638
1.93
5.30
5.9
3.8
36.51
36.85
g/l
0.25
89
601
168
1331
2.11
5.27
10.6
6.2
75.37
71.23
u/l
0.64
163
1241
10
13
8.00
4.90
1.4
1.7
—
—
—
0
0
188
1577
2.32
4.78
5.6
4.3
14.41
14.33
pmol/l
0.17
176
1456
140
1061
1.88
4.74
13.8
8.1
3.92
3.89
e9/l
0.05
122
929
95
638
1.86
4.74
1.8
1.8
82.45
97.36
pmol/l
2.27
42
321
83
537
1.88
4.64
4.2
2.9
2.36
2.35
mmol/l
0.09
72
480
98
670
1.83
4.58
6.4
4.4
1.21
1.22
mmol/l
0.46
93
613
104
741
1.77
4.12
7.1
4.9
1.21
1.22
mmol/l
0.58
86
630
13
31
4.39
4.08
4.0
2.7
3.62
4.84
e9/l
1.03
13
31
13
31
4.39
4.08
4.1
3.3
55.69
59.29
%
0.43
13
31
51
296
1.94
3.88
2.0
2.7
554.46
657.71
ng/l
0.24
40
244
124
941
1.73
3.84
4.9
3.7
6.38
6.24
mmol/l
0.36
116
829
44
244
2.00
3.81
3.0
2.7
4.77
4.58
e6/l
0.03
16
116
124
943
1.72
3.79
4.3
3.4
0.00
0.02
estimate
0.50
26
179
123
934
1.72
3.78
4.2
3.3
0.00
0.00
estimate
-0.00
27
191
123
934
1.72
3.78
6.4
4.6
0.00
0.01
estimate
0.50
26
184
45
255
1.96
3.66
3.0
2.6
0.77
1.00
e6/l
0.28
16
128
46
263
1.95
3.65
3.3
2.9
100.82
188.07
ng/l
0.38
28
153
22
93
2.52
3.62
2.0
1.4
—
—
—
0
0
8
13
6.34
3.53
2.6
1.6
—
—
—
0
0
8
13
6.34
3.53
2.6
1.6
—
—
—
0
0
75
506
1.73
3.48
2.3
2.9
11.17
19.43
ng/l
2.45
31
263
36
192
2.05
3.46
3.6
2.2
4.63
5.34
umol/l
0.33
30
161
12
32
3.90
3.44
2.1
1.4
—
—
—
0
0
107
797
1.67
3.42
3.2
2.1
75.99
75.90
nmol/l
0.01
102
720
9
18
5.16
3.41
1.1
1.2
—
—
—
0
0
10
23
4.50
3.35
2.3
1.4
—
—
—
0
0
10
23
4.50
3.35
2.3
1.4
—
—
—
0
0
8
15
5.49
3.22
1.3
1.7
—
—
—
0
0
7
11
6.53
3.21
1.3
1.9
—
—
—
0
0
9
20
4.64
3.15
2.2
1.6
—
—
—
0
0
23
107
2.28
3.09
4.4
3.5
1.23
1.23
mmol/l
0.01
23
91
11
31
3.68
3.03
2.2
1.4
—
—
—
0
0
37
210
1.92
2.98
1.4
1.3
133.22
190.03
iu/ml
0.38
11
93
29
151
2.06
2.97
3.0
1.7
—
—
—
0
0
11
32
3.56
2.94
1.6
1.3
—
—
—
0
0
11
32
3.56
2.94
1.6
1.3
—
—
—
0
0
40
235
1.86
2.91
2.6
1.7
—
—
—
0
0
7
13
5.52
2.89
2.4
1.8
—
—
—
0
0
6
9
6.81
2.88
2.7
1.3
—
—
—
0
0
14
54
2.70
2.76
1.6
2.6
1.78
1.36
g/l
0.55
14
48
28
151
1.98
2.62
2.9
1.6
—
—
—
0
0
5
7
7.27
2.56
1.0
1.3
2.08
2.47
mg/l
—
5
7
6
11
5.57
2.56
1.3
1.9
—
—
—
0
0
15
63
2.48
2.52
3.7
1.9
—
—
—
0
0
44
279
1.72
2.48
3.1
2.4
2.46
2.42
mmol/l
0.84
34
240
11
38
2.99
2.45
1.3
1.3
—
—
—
0
0
63
442
1.60
2.41
3.6
1.9
—
—
—
0
0
185
1654
1.74
2.38
3.7
3.3
1.36
1.16
mmol/l
2.22
179
1542
193
1747
1.85
2.37
4.0
3.6
4.79
4.79
mmol/l
0.02
186
1645
192
1736
1.83
2.36
3.9
3.6
1.57
1.57
mmol/l
0.04
185
1629
53
358
1.63
2.36
3.3
3.5
4.23
11.61
mg/mmol
0.91
27
204
34
203
1.80
2.35
3.0
1.8
28.99
29.10
s
0.05
34
198
80
597
1.53
2.33
3.9
2.5
27.34
27.39
u/l
0.01
73
571
61
428
1.59
2.33
3.0
2.0
2.64
2.68
mg/l
0.06
53
362
13
53
2.54
2.32
1.5
3.0
24.85
24.62
mmol/l
0.14
13
53
26
143
1.93
2.31
1.8
1.3
237.22
281.14
u/ml
0.08
26
131
18
86
2.19
2.30
2.2
1.5
—
—
—
0
0
92
711
1.51
2.26
4.3
3.3
—
—
—
0
0
194
1766
1.83
2.24
4.5
4.0
2.86
2.85
mmol/l
0.06
186
1652
204
1888
2.11
2.23
19.7
10.5
23.60
18.94
mg/l
1.01
166
1415
158
1369
1.55
2.21
5.6
3.7
11.82
9.50
mm/h
1.50
149
1251
8
24
3.42
2.20
2.5
1.4
—
—
—
0
0
7
19
3.77
2.17
2.4
1.4
—
—
—
0
0
6
14
4.37
2.16
1.3
1.7
—
—
—
0
0
197
1808
1.86
2.12
6.5
5.0
1.63
1.74
mu/l
0.90
189
1696
11
43
2.64
2.11
1.2
1.4
—
—
—
0
0
10
37
2.78
2.10
1.4
1.3
—
113.63
—
0
8
55
386
1.57
2.08
1.4
1.3
19.88
9.39
u/ml
0.28
13
149
16
76
2.19
2.08
1.8
2.2
39.19
40.80
u/l
0.11
16
68
55
388
1.56
2.03
1.4
1.3
26.15
16.25
iu/ml
0.54
13
117
10
38
2.71
2.03
4.3
4.0
0.93
1.18
mg/l
—
10
32
189
1720
1.70
2.02
16.8
9.2
92.80
90.94
ml/min/173m2
0.60
158
1359
187
1709
1.63
1.82
4.2
3.6
5.65
5.63
mmol/l
0.11
176
1581
7
23
3.11
1.81
1.3
1.1
—
—
—
0
0
7
23
3.11
1.81
1.3
1.2
10.07
35.17
nmol/l
—
7
18
7
23
3.11
1.81
1.3
1.1
—
—
—
0
0
58
426
1.49
1.77
2.5
1.8
1.18
0.84
mg/l
0.31
43
309
30
189
1.68
1.74
2.6
2.2
1957.49
3707.24
u/l
0.37
14
82
8
30
2.73
1.74
5.6
2.0
—
—
—
0
0
7
24
2.98
1.73
1.3
1.1
—
—
—
0
0
7
24
2.98
1.73
1.3
1.1
—
—
—
0
0
7
24
2.98
1.73
1.3
1.1
—
—
—
0
0
8
31
2.64
1.67
1.3
1.0
—
—
—
0
0
5
15
3.38
1.53
3.2
1.3
—
—
—
0
0
62
476
1.42
1.49
3.8
3.7
0.00
0.01
estimate
0.80
26
185
6
22
2.77
1.44
1.2
1.4
—
—
—
0
0
169
1539
1.42
1.40
3.8
3.8
—
—
—
0
0
23
144
1.67
1.39
3.0
4.2
22.75
9.01
ug/l
0.28
13
113
6
24
2.54
1.31
1.7
1.9
—
—
—
0
0
6
25
2.44
1.25
1.5
1.2
—
—
—
0
0
9
170
0.51
1.24
1.6
1.4
—
—
—
0
0
9
171
0.51
1.24
1.6
1.4
—
—
—
0
0
9
171
0.51
1.24
1.6
1.4
—
—
—
0
0
9
171
0.51
1.24
1.6
1.4
—
—
—
0
0
23
149
1.61
1.23
3.4
2.9
—
—
—
0
0
12
64
1.93
1.20
5.9
8.3
95.91
94.56
%
0.66
12
64
6
26
2.34
1.19
1.0
1.1
—
—
—
0
0
10
180
0.53
1.12
1.4
1.5
—
—
—
0
0
5
22
2.30
1.04
1.4
1.2
—
—
—
0
0
13
210
0.60
1.01
1.4
1.4
—
—
—
0
0
21
303
0.66
1.01
1.4
1.5
—
—
—
0
0
34
252
1.41
1.00
2.3
1.6
1373.32
1091.29
nmol/l
0.93
28
185
13
77
1.73
0.97
1.7
1.6
—
—
—
0
0
116
1030
1.27
0.96
3.5
2.8
74.61
64.97
ug/l
0.23
108
961
12
70
1.76
0.94
1.2
1.3
—
—
—
0
0
165
1534
1.30
0.92
5.2
4.2
39.51
37.60
mmol/mol
1.40
154
1437
8
43
1.89
0.88
2.3
2.2
3.41
3.66
g/l
—
8
43
8
43
1.89
0.88
2.3
2.2
—
—
—
0
0
8
43
1.89
0.88
2.3
2.2
7.31
7.57
g/l
—
8
43
14
210
0.64
0.82
2.0
1.5
—
—
—
0
0
21
148
1.46
0.81
2.1
1.7
—
—
—
0
0
105
935
1.24
0.81
3.9
2.4
—
—
—
0
0
6
34
1.79
0.77
2.5
2.4
0.00
0.00
g/l
—
6
34
6
34
1.79
0.77
2.5
2.4
0.00
0.00
g/l
—
6
34
7
38
1.87
0.74
1.6
1.7
—
—
—
0
0
5
25
2.02
0.73
1.6
1.2
—
—
—
0
0
5
25
2.02
0.73
5.0
1.3
—
—
—
0
0
19
136
1.43
0.69
1.4
1.3
—
—
—
0
0
7
42
1.69
0.69
2.4
2.2
2.89
3.01
g/l
—
7
42
12
78
1.57
0.67
1.5
1.9
2.83
4.00
ug/l
0.49
12
67
6
35
1.73
0.58
2.7
2.4
0.00
0.00
g/l
—
6
35
6
35
1.73
0.58
2.7
2.4
38.67
39.11
g/l
—
6
35
8
54
1.50
0.58
2.4
2.1
0.86
1.15
%
—
8
54
54
464
1.22
0.57
1.6
1.6
1.74
1.29
mmol/l
0.93
45
405
6
37
1.64
0.56
2.7
2.4
4.05
1.06
g/l
—
6
37
136
1272
1.18
0.55
2.8
2.7
34.86
31.95
u/l
0.31
131
1210
11
74
1.51
0.54
1.6
1.6
—
—
—
0
0
23
184
1.28
0.45
7.5
4.3
—
—
—
0
0
6
91
0.65
0.43
2.8
2.4
—
—
—
0
0
11
150
0.72
0.43
1.1
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.6
—
—
—
0
0
16
124
1.31
0.40
1.8
2.6
72.00
80.67
ml/min/173m2
—
5
51
5
35
1.44
0.39
1.2
1.0
—
—
—
0
0
5
36
1.40
0.38
1.8
1.1
44.20
258.58
ug/l
—
5
30
30
257
1.19
0.34
1.2
1.5
1.38
1.30
%
0.50
24
229
6
45
1.34
0.34
2.3
1.2
4.38
3.66
mmol/l
—
6
38
59
539
1.13
0.30
1.4
1.3
0.53
1.43
u/ml
1.71
18
130
8
62
1.30
0.28
1.3
1.1
—
—
—
0
0
46
507
0.88
0.28
2.6
2.2
—
—
—
0
0
8
63
1.28
0.28
1.3
1.1
—
—
—
0
0
9
120
0.74
0.28
1.3
1.4
—
—
—
0
0
14
114
1.24
0.25
1.4
1.3
250.72
273.35
miu/ml
—
7
54
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
43
467
0.90
0.21
2.3
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
127.99
—
0
14
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
14
118
1.20
0.19
1.4
1.6
—
—
—
0
0
6
51
1.18
0.19
3.8
3.1
27.83
34.30
u/ml
—
6
51
17
147
1.17
0.18
1.4
1.3
—
50.79
—
0
8
7
62
1.13
0.17
1.4
1.4
—
—
—
0
0
7
62
1.13
0.17
1.4
1.1
—
—
—
0
0
12
101
1.20
0.17
1.3
1.5
—
—
—
0
0
8
69
1.17
0.16
1.5
1.8
—
—
—
0
0
13
148
0.87
0.13
1.2
1.6
—
—
—
0
0
5
45
1.11
0.10
1.2
1.3
—
—
—
0
0
5
65
0.76
0.08
1.8
1.8
—
—
—
0
0
18
166
1.09
0.08
2.9
2.2
—
19.05
—
0
10
31
323
0.95
0.05
2.2
1.9
—
—
—
0
0
26
249
1.05
0.04
1.9
1.8
—
—
—
0
0
60
591
1.02
0.02
1.5
1.5
—
—
—
0
0
10
93
1.08
0.02
2.2
1.8
—
—
—
0
0
57
573
0.99
0.00
1.9
1.6
—
—
—
0
0
7
72
0.97
0.00
1.1
1.1
—
12.21
—
0
14
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
7.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
77.78
—
0
9
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
30.44
—
0
9
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
12
120
1.00
-0.00
2.1
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
22.28
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
1792.13
—
0
8
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_OVARDYSNAS and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_OVARDYSNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_OVARDYSNAS – Ovarian dysfunction, other/unspecified
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data